Valneva SE
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VALN research report →
About the company
Valneva SE operates as a specialized biopharmaceutical company, concentrating its efforts on developing and bringing to market preventative vaccines for infectious diseases where current medical options are insufficient. Its portfolio of commercial travel vaccines includes IXIARO, an inactivated vaccine derived from Vero cell culture, which provides active immunity against Japanese encephalitis. Another offering is DUKORAL, an oral vaccine designed to guard against diarrhea induced by Vibrio cholerae or enterotoxigenic Escherichia coli (ETEC) bacteria.
- CEO
- Thomas Lingelbach
- IPO
- 2021
- Employees
- 713
- HQ
- Saint-Herblain, FR
Price Chart
- Market Cap
- $495.45M
- P/E
- -2.88
- P/S
- 2.84
- P/B
- 5.24
- EV/EBITDA
- -6.32
- Div Yield
- 0.00%
- Gross Margin
- 29.46%
- Op Margin
- -68.81%
- Net Margin
- -88.30%
- ROE
- -106.22%
- ROIC
- -36.00%
- Revenue
- $174.66M · 3.00%
- Net Income
- $-115,192,000 · -840.57%
- EPS
- $-1.32 · -656.88%
- Op Income
- $-81,631,000
- FCF YoY
- 31.42%
- 52W High
- $12.25
- 52W Low
- $5.04
- 50D MA
- $5.55
- 200D MA
- $8.32
- Beta
- 1.40
- Avg Volume
- 51.07K
Get TickerSpark's AI analysis on VALN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our VALN coverage
Recent articles, reports, and earnings notes.
No research on VALN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VALN report →Similar companies
Peers in the same neighborhood.